Oruka Therapeutics, Inc. is a biotechnology company.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-121.97M |
| Operating Margin | 0.00% |
| Return on Equity | -24.70% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.63 |
| Price-to-Book | 7.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $59.86M |
| Float | $37.72M |
| % Insiders | 1.41% |
| % Institutions | 92.39% |
Volatility is currently expanding